免疫功能损害的患者，如那些患有血液系统恶性肿瘤的患者，更容易感染SARS-CoV-2病毒，出现严重后果和死亡风险。Tixagevimab / cilgavimab是一种单克隆抗体组合，可以与SARS-CoV-2病毒的尖刺蛋白结合。PROVENT第III期临床试验报告称，Tixagevimab / cilgavimab预防显著降低了免疫功能损害参与者感染COVID-19的风险。然而，该试验在Omicron变体流行之前进行。本系统性回顾和荟萃分析提供了Tixagevimab / cilgavimab在免疫功能损害患者中的最新实际效果概述，包括血液系统恶性肿瘤患者。包括自2021年1月1日至2022年10月1日的临床研究，报道了Tixagevimab / cilgavimab后的COVID-19爆发感染。还对与COVID-19相关的住院、重症监护和死亡进行了评估。进行元分析确定总体临床效果。本回顾纳入了18项研究，共计25345名免疫功能损害参与者，其中包括5438名患有血液系统病理学的患者。总体临床效果为40.54％，住院率、重症监护率和COVID-19特异性死亡率分别为66.19％，82.13％和92.39％。本研究强调了Tixagevimab / cilgavimab在Omicron主导时期减少免疫抑制个体，包括患有血液系统恶性肿瘤的患者，COVID-19感染和严重后果的临床效果。真实世界的研究对于为免疫功能损害患者抗击新的SARS-CoV-2变体提供持续的临床效益确证很重要。©2023年作者。英国血液学杂志由英国血液学协会和约翰威立出版社出版。

Immunocompromised patients, such as those with a haematological malignancy, are at higher risk of SARS-CoV-2 infection, severe outcomes and mortality. Tixagevimab/cilgavimab is a monoclonal antibody combination which binds to the SARS-CoV-2 spike protein. The PROVENT phase III clinical trial reported that tixagevimab/cilgavimab prophylaxis significantly reduced the risk of COVID-19 infection in immunocompromised participants. However, the trial was conducted before the Omicron variant became prevalent. This systematic review and meta-analysis provide an up-to-date summary of the real-world effectiveness of tixagevimab/cilgavimab in immunocompromised patients, including patients with haematological malignancies. Clinical studies from 1 January 2021 to 1 October 2022, which reported breakthrough COVID-19 infections after tixagevimab/cilgavimab, were included. COVID-19-related hospitalisations, intensive care admissions and mortality were also assessed. A meta-analysis was performed to ascertain overall clinical effectiveness. Eighteen studies, with 25 345 immunocompromised participants, including 5438 patients with haematological pathologies, were included in the review. The overall clinical effectiveness of tixagevimab/cilgavimab against COVID-19 breakthrough infection, hospitalisation, intensive care admission and COVID-19-specific mortality was 40.54%, 66.19%, 82.13% and 92.39%, respectively. This review highlights the clinical effectiveness of tixagevimab/cilgavimab at reducing COVID-19 infection and severe outcomes for immunosuppressed individuals, including patients with a haematological malignancy, during the Omicron-predominant era. Real-world studies are important to provide ongoing certainty of the clinical benefit for immunocompromised patients against new SARS-CoV-2 variants.© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.